Rimonabant (also known as SR141716; trade name Acomplia) ) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite.
This page contains content from the copyrighted Wikipedia article "Rimonabant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
